Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vyteris redirects business strategy
The company will de-emphasize its marketing efforts related to its LidoSite product. As a result, the company will immediately reduce its workforce by approximately 32 employees that were
The company will de-emphasize its marketing efforts related to its LidoSite product. As a result, the company will immediately reduce its workforce by approximately 32 employees that were
David Gao, CEO of Beijing Med-Pharm, said: “We believe Rongheng’s established, tier-one distribution network will bolster our national presence to include Shanghai, one of China’s most compelling healthcare
Under the terms of the agreement Nycomed will share brand responsibilities and expenses with Paladin and will deploy a national primary care sales force to promote Tridural. Paladin
The analysis showed that MN-166 decreased the formation of black holes (permanent brain lesions believed to indicate the death of nerves in the brain) on magnetic resonance imaging
Eisai had planned to submit an NDA under Subpart H, based on Phase II clinical trial data, to seek accelerated approval for E7389 as a third-line breast cancer
Granisetron hydrochloride tablets are the generic version of Roche’s Kytril tablets and will be shipped immediately.
The patent also provides for a method to automatically release all applied pressure to the atmosphere in the event of a system or power failure as a safety
The trial aims to validate the use of circulating fetal cells in early prenatal detection of Down syndrome within the first trimester of pregnancy. Ikonisys expects this solution
Peter Zerhouni is currently director of business development at Diamyd Medical. Elisabeth Lindner, president and CEO of Diamyd Medical, said: “Peter will give a major contribution to the
Empire Asset Management Company acted as the sole placement agent for the transaction.